Navigation Links
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Date:3/12/2009

trial demonstrated the following key results:

  • A zero percent rate of stent thrombosis (blood clot formation) for all patients out to two years of follow up.
  • No new major adverse cardiac events (MACE) between six months and two years. At two years, the bioabsorbable device demonstrated a MACE rate of 3.6 percent (one patient). MACE is defined as any event that resulted in re-treatment of the treated artery lesion, heart attack or cardiac death.
  • Bioabsorption of the stent at two years after implantation, as confirmed by an assessment of the stent struts using optical coherence tomography (OCT).
  • Restoration of vasomotion (ability of the blood vessel to contract and expand) was observed at two years, with the drug acetylcholine used in nine patients showing vasodilation in the previously stented area, and the drug methergin used in seven patients showing vasoconstriction in the previously stented area.
  • Reduction in plaque area in treated arteries, corresponding to an increase in blood flow between six months and two years, as confirmed by intravascular ultrasound (IVUS) and virtual histology.

"Abbott's bioabsorbable stent may be a major breakthrough in the treatment of narrowed coronary arteries. The two-year ABSORB trial results show that the bioabsorbable device did its job of relieving coronary obstructions and preventing re-narrowing, and that it did this safely," said John Ormiston, M.D., medical director at Mercy Hospital in Auckland, New Zealand and principal investigator in the first phase of the ABSORB trial. "With no rigid stent remaining, vasomotion - the natural movement of the artery - was restored, and the artery appeared to behave like a normal artery. Who would want a permanent device if a temporary one may do the job and then disappear?"

Abbott is the only company with long-term clinical
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
4. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
7. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
8. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
9. SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa
10. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
11. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that agreement has been reached with ... the design of a pivotal, Phase 3 clinical ... the treatment of cutaneous T-cell lymphoma (CTCL).  ...
(Date:9/16/2014)... , 17. September 2014 /PRNewswire/ ... HOLX ), hat heute die Markteinführung ... präanalytischen Probenverarbeitung, in Europa bekannt gegeben. ... vollautomatisierte Universalplattform zur Vereinfachung der präanalytischen ... ineffiziente und fehlerbehaftete Arbeitsschritte bei der ...
(Date:9/16/2014)... , Sept. 16, 2014 A study led ... has found the chemotherapy dose threshold below which male ... production. The study appears in September 17 edition of ... clarifying which patients are at highest risk for reduced ... eventually increase use of pre-treatment fertility preservation methods such ...
Breaking Medicine Technology:Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 3Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4
... Pressure and Triglycerides Also Observed , , NEW ORLEANS, ... ), Eli Lilly and Company (NYSE: LLY ), ... long-term, interim results from the DURATION-1 study that showed sustained ... systolic blood pressure and triglycerides, through two years of treatment ...
... June 7 New Phase II data presented today at ... show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) ... weekly, biweekly and monthly dosing. Reducing blood sugar is ... that affects over 250 million people worldwide. , ...
Cached Medicine Technology:Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 2Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 3Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 4Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 5Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 6Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 7Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 2Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 3
(Date:9/17/2014)... Tampa, FL (PRWEB) September 17, 2014 Tina ... ), is finishing up her chemotherapy but not her fight ... up for the Komen Florida Suncoast “Race for the Cure” ... “I registered for the Komen Race for the Cure because ... breast cancer,” Griffin said. , As part of her efforts, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Four ... eighth annual Wailea Tennis Fantasy Camp on ... Maui’s prestigious Wailea Tennis Club, with three-time grand slam ... returning to Wailea, Maui for her fifth year. , ... match play with Davenport, recently inducted into the International ...
(Date:9/17/2014)... September 17, 2014 A raucous childhood ... come together to form author Nancy Chovancek’s laughter-filled new ... is a collection of short stories that prove the ... fun. With a positive message of empowerment and resilience, ... is a proven author with two books under her ...
(Date:9/17/2014)... This September 18-20, 22 participating developmentally-disabled athletes ... three stage outdoor sporting event in non-profit World T.E.A.M. ... , Hosted at The Center for Discovery ... five participating teams coached by able-bodied athletes. For each ... provide expert guidance as well as technical assistance. Like ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Lee ... settlement industry, will be appearing on The Balancing Act® ... two September episodes. , The segment will premiere on ... on 'The Balancing Act® airing on Lifetime Television®' with ... of Asset Funding Corp. for over a decade and ...
Breaking Medicine News(10 mins):Health News:Tina Griffin’s Fight Against Cancer Didn’t Stop With her Chemotherapy—Her Next Step Is to Run in the Suncoast ‘Race for the Cure’ Oct. 11 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 3Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 3Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2
... Polyp Detection by Thirteen Percent, SAN DIEGO, ... in San Diego (DDW 2008), world-renowned gastroenterologist,Jerome D. ... which evaluated the efficacy of the Third Eye(TM) ... physicians to visualize,abnormalities in the colon., The ...
... near Mosul in 2003 , , WEDNESDAY, May 21 (HealthDay News) ... near Mosul, Iraq, in 2003 returned home with a debilitating ... , But doctors were only able to diagnose the condition, ... to reliably identify the problem, said the authors of a ...
... (Amex: QGP, QGP.WSA, QGP.WSB) ( http://www.QuantumMD.com ) ... plan. The Company,increased its employment base by 23% since ... ft. to 10,600 sq. ft., and has moved a,branch ... Doral (west,Miami), Florida., Susan Darby Guillama, Executive Vice ...
... MINNEAPOLIS, May 21 ACM today announced a ... development efforts on,providing next generation technology and services ... of healthcare today: commercial plans and,payers, and federal ... Development Gary Loeber has been,named EVP/General Manager for ...
... that patients with chronic obstructive pulmonary disease (COPD) who ... visits from exacerbations or complications benefit from simple low-intensity ... for COPD was previously shown to reduce hospitalizations for ... a more limited intervention model is effective, said Kathryn ...
... Calif., May 21 LUMEDX Corporation, a ... information systems,(CVIS), introduces software to manage data ... The Anticoagulation Module empowers clinicians,by making critical ... safety., For more information -- including ...
Cached Medicine News:Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 2Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 3Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 4Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 5Health News:Some Iraq War Vets Suffer Breathing Problems 2Health News:Some Iraq War Vets Suffer Breathing Problems 3Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 3Health News:ACM Taps Two Senior Leaders to Head Up New Strategic Initiatives 2Health News:Low-intensity case management cuts COPD-related hospital visits in half 2Health News:New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 2
... thin collagen coated highly compliant ... thin wall construction offers optimal ... Hemacarotid UltraThin Patch provides superb ... and healing, without suture hole ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... engineered to close arteriotomies with ease ... with a simple trigger actvated mechanism, ... deliver sheath gently locks onto the ... the site before, during, and after ...
Medicine Products: